Pages that link to "Q33917224"
Jump to navigation
Jump to search
The following pages link to Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia (Q33917224):
Displaying 50 items.
- Neoantigen-based cancer immunotherapy (Q26738693) (← links)
- Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer (Q26744758) (← links)
- Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment (Q26783055) (← links)
- Neoepitopes of Cancers: Looking Back, Looking Ahead (Q26784047) (← links)
- The next steps in next-gen sequencing of cancer genomes (Q26998894) (← links)
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. (Q27310763) (← links)
- Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies (Q28067817) (← links)
- Update on immune checkpoint inhibitors in gynecological cancers (Q28076497) (← links)
- Tumor neoantigens: building a framework for personalized cancer immunotherapy (Q28082704) (← links)
- Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer (Q29615679) (← links)
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (Q31117752) (← links)
- TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection (Q33630241) (← links)
- Identification of trunk mutations in gastric carcinoma: a case study (Q33921459) (← links)
- Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity (Q34375163) (← links)
- Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations (Q34398369) (← links)
- Neoantigens in cancer immunotherapy. (Q34470074) (← links)
- Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen (Q35799065) (← links)
- Haematological malignancies: at the forefront of immunotherapeutic innovation (Q35880618) (← links)
- Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution (Q35909370) (← links)
- Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. (Q36021163) (← links)
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). (Q36024656) (← links)
- A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer (Q36188919) (← links)
- Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. (Q36316627) (← links)
- MuPeXI: prediction of neo-epitopes from tumor sequencing data. (Q36352986) (← links)
- pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens (Q36521595) (← links)
- The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference (Q36553815) (← links)
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (Q36850230) (← links)
- Molecular and genetic properties of tumors associated with local immune cytolytic activity (Q36869059) (← links)
- A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma (Q36939300) (← links)
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (Q37046405) (← links)
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (Q37193493) (← links)
- Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy (Q37370230) (← links)
- Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming (Q37457945) (← links)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (Q37517482) (← links)
- Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. (Q37587362) (← links)
- Designer vaccine nanodiscs for personalized cancer immunotherapy (Q37730767) (← links)
- Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer (Q38244094) (← links)
- Therapeutic targeting of tumor suppressor genes (Q38306663) (← links)
- Immunogenic peptide discovery in cancer genomes. (Q38318484) (← links)
- Synthetic biology in cell-based cancer immunotherapy (Q38531361) (← links)
- The neoepitope landscape in pediatric cancers. (Q38601828) (← links)
- An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors (Q38603909) (← links)
- Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells (Q38647855) (← links)
- Engineered Materials for Cancer Immunotherapy. (Q38660577) (← links)
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic (Q38669465) (← links)
- HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model (Q38706874) (← links)
- NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis (Q38730355) (← links)
- Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia (Q38752567) (← links)
- The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer (Q38753386) (← links)
- Unmasking targets of antitumor immunity via high-throughput antigen profiling (Q38787035) (← links)